This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Learn about the efficacy and safety of Somavert, its tumour impact and its effect on co-morbidity management through clinical and real world data

The acromegaly disease activity tool designed to help monitor your patients

Advice and support services to help you and your patients optimise your experience with Somavert about the efficacy and safety of Somavert through clinical and real world data

Learn about funding and reimbursement England, Scotland, Wales and Northern Ireland

Watch and listen to acromegaly experts talk about various topics in the disease area as well as recordings from our National Nurse Meeting and the Acromegaly co-morbidity series

Click here for Somavert® (pegvisomant) Prescribing Information. Adverse event reporting information can be found at the bottom of the page.

Somavert is used in the treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-I concentrations or was not tolerated.

Personalised dosing

Somavert has a positive dose response, allowing flexible dose titration to achieve IGF-I normalisation and improve symptoms1,2

IGF-I normalisation rates with increasing dose strengths

Percentage of Somavert patients achieving IGF-I normalisation after 12 weeks of treatment2
*p=0.02. **p<0.001

Somavert is a daily subcutaneous injection available in five vial sizes of 10 mg, 15 mg, 20 mg, 25 mg and 30 mg

The daily dose of Somavert should be adjusted ±5 mg every 4–6 weeks to achieve and maintain IGF-I normalisation and optimal therapeutic response. A loading dose of 80mg pegvisomant should be administered subcutaneously under medical supervision1

  • Any daily dose can be self-administered with a single injection1
  • No need for patients to visit a clinic after their loading dose is administered in hospital
  • No time or food restrictions
  • Pre-filled diluent syringe with enlarged finger grip and plunger for convenience
  • Powder vials must should be stored in the fridge. However, they may be stored at room temperature up to a maximum of 25°C for a single period of up to 30 days.
  • Diluent syringe can be kept out of the fridge (<30°C) prior to reconstitution​​​​​​​

Please refer to the Summary of Product Characteristics for the full information about storage

Homecare services 

We offer a range of services that help your patients at home with medication delivery and face-to-face support 

Learn more

The Somavert prescribing guide

Find information on funding, homecare and follow-up

Download the guide

Somavert efficacy

Discover IGF-I normalisation rates with Somavert

Learn more

Explore more

Contact us

To find out more about Somavert dosing, supporting your patients or to order starter kits

Contact us

** This is an optional area where footnotes can live.

Monitoring patients with ACRODAT

Track IGF-I, symptoms and co-morbidities to help monitor and optimise support for your acromegaly patients at every stage of their journey

Learn more

** This is an optional area where footnotes can live.

1. Somavert Summary of Product Characteristics.  Available here
2. Trainer PJ, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med 2000;342(16):1171–7.

PP-SOM-GBR-1014. September 2021

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020